EPRX (EPRX) Stock Price & Analysis
EPRX (EPRX) rose 12.00% to USD 8.4 as of September 8, 2026 at 03:29 UTC, according to Nexqual real-time market data.
EPRX last closed at USD 7.5; the session ranged USD 7.39–8.4 on volume of 3,520,931 shares. Market capitalization is $555.02M, with a 52-week range of USD 5.15–9.32 (NMS). Source: Nexqual, September 8, 2026 at 03:29 UTC.
Key Statistics (as of September 8, 2026 at 03:29 UTC)
| Price | USD 8.4 |
|---|---|
| Change | ▲ 12.00% (up) |
| Previous Close | USD 7.5 |
| Open | USD 7.45 |
| Day Range | USD 7.39 – 8.4 |
| 52-Week Range | USD 5.15 – 9.32 |
| Volume | 3,520,931 shares |
| Market Cap | $555.02M |
| Exchange | NMS |
Technical Analysis (EPRX)
Nexqual's technical model rates EPRX "BUY" based on 5 bullish and 2 bearish signals across 128 daily candles, as of September 8, 2026 at 03:29 UTC.
| Overall Signal | BUY |
|---|---|
| RSI (14) | 69.49 (neutral) |
| vs SMA50 | Above (USD 6.68) |
| MACD | 0.25 (positive) |
Analyst Ratings (EPRX)
Wall Street analysts rate EPRX "Strong Buy" based on 10 analysts, with a mean price target of USD 16.35 (range USD 11–25), per Nexqual as of September 8, 2026 at 03:29 UTC.
| Consensus Rating | Strong Buy |
|---|---|
| Analyst Count | 10 |
| Mean Target | USD 16.35 |
| High Target | USD 25 |
| Low Target | USD 11 |
| Buy / Hold / Sell | 11 / 0 / 0 |
Earnings (EPRX)
| Next Earnings Date | 2026-11-03 |
|---|---|
| EPS Estimate | USD -0.26 |
| Revenue Estimate | $0 |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD -0.23 vs est -0.23 ▲ beat |
| 2025-12-31 | USD -0.37 vs est -0.16 ▼ miss |
| 2025-09-30 | USD -0.19 vs est -0.19 ▲ beat |
Source: Nexqual, September 8, 2026 at 03:29 UTC.
Financials & Fundamentals (EPRX)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| ROE | -66.70% |
| Debt / Equity | 1.42 |
| Current Ratio | 16 |
| Total Cash | $133.66M |
| Total Debt | $1.84M |
| Free Cash Flow | $-18.93M |
Source: Nexqual, September 8, 2026 at 03:29 UTC.
Financial Health Score (EPRX)
Nexqual rates EPRX's overall financial health "Mixed" across five dimensions, as of September 8, 2026 at 03:29 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Weak — Pre-revenue or very early stage |
| Balance Sheet | Strong — $134M cash vs $2M debt, net cash position |
| Cash Flow | Weak — Operating cash flow -$37M |
| Efficiency | Critical — ROE -67%, ROA -43.7% |
Ownership (EPRX)
| Insider Ownership | +13.98% |
|---|---|
| Institutional Ownership | +43.18% |
| Shares Outstanding | 66.07M |
| Float | 55.67M |
Source: Nexqual, September 8, 2026 at 03:29 UTC.
Leadership (EPRX)
EPRX is led by James A. Helliwell FRCPC (age 51), CEO & Director, per Nexqual as of September 8, 2026 at 03:29 UTC.
| CEO & Director | James A. Helliwell FRCPC (age 51) |
|---|---|
| Chief Financial Officer | Alexander John Rothwell Eng. (age 56) |
| Executive Vice President Corporate Services & People | Wajida Leclerc B.A., CCP, CHRP (age 65) |
| Executive Vice President of Technical Operations | Jeffrey Millard (age 49) |
Major Backers & Investors (EPRX)
Notable institutional backers of EPRX include Beutel, Goodman & Company Ltd, Affinity Asset Advisors, Llc, Balyasny Asset Management LP, according to Nexqual as of September 8, 2026 at 03:29 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Beutel, Goodman & Company Ltd | 5.58% |
| Affinity Asset Advisors, Llc | 2.54% |
| Balyasny Asset Management LP | 2.08% |
| Vivo Capital, LLC | 2.08% |
| Scotia Capital Inc. | 2.07% |
| Pfm Health Sciences, Lp | 1.86% |
| Great Point Partners LLC | 1.85% |
| Jupiter Topco LLC | 1.61% |
Source: Nexqual, September 8, 2026 at 03:29 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| LXEO | Lexeo Therapeutics, Inc. | USD 4.89 | ▲ 2.3% |
| ENGN | enGene Therapeutics Inc. | USD 1.82 | ▼ 3.7% |
| CTNM | Contineum Therapeutics, Inc. | USD 16.7 | ▼ 3.13% |
| AVBP | ArriVent BioPharma, Inc. | USD 30.95 | ▲ 1.44% |
| ZURA | Zura Bio Limited | USD 6.23 | ▲ 9.88% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: September 8, 2026 at 03:29 UTC. This page is informational and not investment advice.